Tocagen Inc (NASDAQ:TOCA) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Thursday.

According to Zacks, “Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company which focuses on retroviral gene therapy platforms. The company’s lead product candidate consists of Toca 511 & Toca FC, initially for the treatment of recurrent high grade glioma, a disease with a significant unmet medical need. Tocagen, Inc. is based in San Diego, United States. “

Separately, Stifel Nicolaus reaffirmed a “buy” rating and set a $24.00 price objective on shares of Tocagen in a research report on Tuesday, July 25th.

Tocagen (NASDAQ:TOCA) opened at 12.49 on Thursday. Tocagen has a 52-week low of $9.68 and a 52-week high of $17.95. The company’s market capitalization is $247.41 million. The company has a 50 day moving average of $12.13 and a 200 day moving average of $13.43.

Tocagen (NASDAQ:TOCA) last posted its quarterly earnings data on Wednesday, August 9th. The company reported ($0.56) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.52) by ($0.04). The firm had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.01 million. On average, equities research analysts forecast that Tocagen will post ($2.51) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Tocagen Inc (TOCA) Raised to Hold at Zacks Investment Research” was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/14/tocagen-inc-toca-raised-to-hold-at-zacks-investment-research.html.

A number of hedge funds and other institutional investors have recently bought and sold shares of TOCA. EcoR1 Capital LLC purchased a new position in Tocagen in the 2nd quarter worth approximately $18,074,000. FMR LLC purchased a new position in Tocagen in the 2nd quarter worth approximately $9,624,000. Vanguard Group Inc. purchased a new position in Tocagen in the 2nd quarter worth approximately $5,036,000. JPMorgan Chase & Co. purchased a new position in Tocagen in the 2nd quarter worth approximately $4,960,000. Finally, Nicholas Investment Partners LP purchased a new position in Tocagen in the 2nd quarter worth approximately $228,000. 37.87% of the stock is currently owned by institutional investors.

Tocagen Company Profile

Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.

Receive News & Ratings for Tocagen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen Inc and related companies with MarketBeat.com's FREE daily email newsletter.